A 2015 analysis found that the prevalence of irreproducible preclinical research was greater than 50%, correlating with the $28 billion spent annually in the US on basic biomedical research that can’t be successfully repeated. However, most biopharma researchers lack the money or time to do multiple rounds of sequencing on multiple cell line samples until finding the right one. It’s a costly process, but, ultimately, authentication makes studies more predictable.

How does your preclinical study team choose cell lines? Download the playbook that explores how a recent industry collaboration makes it possible to know exactly what you’re getting, right down to the lot — with a new cell line selection tool that is efficient, cost-effective, and eliminates guesswork. Topics include:

• The challenges in cell line selection and tips for choosing the right ones.
• Why authenticated cell line ’omics data can fast-track cell line selection.
• Where to find authenticated cell line ‘omics data.

​